VIRGINIA RETIREMENT SYSTEMS ET Al lessened its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 30.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 82,600 shares of the medical technology company’s stock after selling 35,400 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Medtronic were worth $7,935,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of the company. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the 4th quarter valued at $27,000. Anfield Capital Management LLC boosted its stake in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares in the last quarter. Valley Wealth Managers Inc. acquired a new stake in Medtronic in the 3rd quarter valued at $29,000. Board of the Pension Protection Fund acquired a new stake in Medtronic in the 4th quarter valued at $29,000. Finally, GoalVest Advisory LLC acquired a new stake in Medtronic in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Insider Activity
In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is owned by company insiders.
Medtronic News Roundup
- Positive Sentiment: Medtronic hired a new chief operations and supply chain officer, a move that could help execution and manufacturing efficiency over time. Medtronic hires chief operations and supply chain officer
- Positive Sentiment: Brokerage coverage remains constructive, with Medtronic receiving a consensus “Moderate Buy” and multiple recent buy-equivalent ratings, which can help support the shares. Medtronic PLC (NYSE:MDT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
- Positive Sentiment: Recent updates around Medtronic’s cardiac technology and its collaboration with Orchestra BioMed suggest ongoing pipeline momentum, which may improve long-term growth expectations. Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
- Neutral Sentiment: Several articles mainly discuss why the stock has been trending and how investors are reassessing valuation after recent weakness, but they do not introduce a new fundamental catalyst. Assessing Medtronic (MDT) Valuation After Recent Share Price Weakness
- Neutral Sentiment: Orchestra BioMed’s BACKBEAT trial update is constructive for the partnership, but the key readout is not expected until 2027, so the near-term stock impact may be limited. Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
- Negative Sentiment: Recent reports also point to continued share-price weakness, with Medtronic down sharply over the past month and quarter, reflecting caution around growth and execution. Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note
- Negative Sentiment: News that Medtronic is closing a California site may raise concerns about restructuring costs or operational disruption, adding to investor caution. Medtronic to close California site
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. CICC Research started coverage on Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating for the company. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings downgraded Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, April 21st. Mizuho dropped their target price on Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Finally, Barclays boosted their target price on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.80.
View Our Latest Report on Medtronic
Medtronic Trading Down 0.8%
NYSE MDT opened at $76.19 on Thursday. The stock has a 50-day simple moving average of $85.55 and a 200 day simple moving average of $93.88. The company has a market capitalization of $97.81 billion, a PE ratio of 21.22, a P/E/G ratio of 1.83 and a beta of 0.62. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $74.40 and a 12 month high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.57 EPS for the current year.
Medtronic Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio is 79.11%.
Medtronic Company Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Articles
- Five stocks we like better than Medtronic
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
